Company Description
Hyperion DeFi, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States.
The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi; and agreement with Formosa Pharmaceuticals.
Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025.
Hyperion DeFi, Inc. was founded in 2014 and is based in New York, New York.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 25, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Michael Rowe |
Contact Details
Address: 295 Madison Avenue, Suite 2400 New York, New York 10017 United States | |
| Phone | 917 289 1117 |
| Website | hyperiondefi.com |
Stock Details
| Ticker Symbol | HYPD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001682639 |
| Employer ID | 47-1178401 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael M. Rowe | Principal Financial Officer, Chief Executive Officer, President and Acting Chairman of the Board |
| Hyunsu Jung | Chief Investment Officer and Director |
| Norbert Lowe | Senior Vice President of Commercial Operations |
| Enrico Brambilla | Senior Vice President of Research & Development |
| Alexander Lobo | Investor Contact |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | 8-K | Current Report |
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Jul 24, 2025 | ARS | Filing |
| Jul 24, 2025 | DEF 14A | Other definitive proxy statements |
| Jul 22, 2025 | D | Notice of Exempt Offering of Securities |
| Jul 22, 2025 | 144 | Filing |
| Jul 18, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 16, 2025 | SCHEDULE 13D | Filing |
| Jul 11, 2025 | PRE 14A | Other preliminary proxy statements |
| Jul 7, 2025 | 424B5 | Filing |